تحميل
NYSEHealthcareDrug Manufacturers - Specialty & Generic
أحدث البيانات المتاحة
18.73 US$
+0.21 US$ · +1.13%
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
الإغلاق السابق
18.73 US$
+0.21 US$ · +1.13%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
نطاق اليوم
السعر الحالي 18.73 US$
نطاق 52 أسبوعًا
السعر الحالي 18.73 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
شراء
تقييم
73
أقل من القيمة
المشاعر
59
مختلط
المخاطر
23
مخاطر متوسطة
الزخم
42
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
نطاق اليوم
السعر الحالي 18.73 US$
نطاق 52 أسبوعًا
السعر الحالي 18.73 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (JPY) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 4.78 ترليون JPY | 4.58 ترليون JPY | 4.26 ترليون JPY | 4.03 ترليون JPY | 3.57 ترليون JPY |
| تكلفة البضاعة المباعة | 2.34 ترليون JPY | 1.58 ترليون JPY | 1.43 ترليون JPY | 1.24 ترليون JPY | 1.11 ترليون JPY |
| الربح الإجمالي | 2.44 ترليون JPY | 3 ترليون JPY | 2.83 ترليون JPY | 2.78 ترليون JPY | 2.46 ترليون JPY |
| البحث والتطوير | 716.69 مليار JPY | 730.23 مليار JPY | 729.92 مليار JPY | 633.33 مليار JPY | 526.09 مليار JPY |
| مصاريف البيع والمصاريف العمومية والإدارية | 1.15 ترليون JPY | 1.1 ترليون JPY | 1.05 ترليون JPY | 997.31 مليار JPY | 886.36 مليار JPY |
| نفقات التشغيل | 1.87 ترليون JPY | 2.66 ترليون JPY | 2.62 ترليون JPY | 2.29 ترليون JPY | 2 ترليون JPY |
| دخل الفوائد | 223.91 مليار JPY | 19.64 مليار JPY | 78.1 مليون JPY | 5.51 مليار JPY | 4.59 مليار JPY |
| مصاريف الفوائد | 379.14 مليار JPY | 137.31 مليار JPY | 1.06 مليار JPY | 116.97 مليار JPY | 122.43 مليار JPY |
| الاستهلاك والإطفاء | 721.13 مليار JPY | 761.4 مليار JPY | 728 مليار JPY | 664.4 مليار JPY | 583.15 مليار JPY |
| الدخل التشغيلي | 573.04 مليار JPY | 342.59 مليار JPY | 214.08 مليار JPY | 490.51 مليار JPY | 460.84 مليار JPY |
| صافي الدخل | 203.33 مليار JPY | 107.93 مليار JPY | 144.07 مليار JPY | 317.02 مليار JPY | 230.06 مليار JPY |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
صناديق متداولة تفصح عن تعرضها لهذا السهم.
First Trust Value Line Dividend Index FundFVD31.9 مليون0.42%7.62 مليار USD0.62%47.66 US$+0.13%
VanEck Pharmaceutical ETFPPH28.35 مليون2.77%1.04 مليار USD0.36%110.49 US$+1.20%
Avantis International Equity ETFAVDE10.34 مليون0.05%19.22 مليار USD0.23%89.80 US$+0.58%
ActivePassive International Equity ETFAPIE2.84 مليون0.25%1.14 مليار USD0.45%38.56 US$+0.65%
Vanguard FTSE All-World ex-US ETFVEU2.22 مليون0.00%98.6 مليار USD0.04%82.82 US$+0.78%
iShares Dynamic Equity Active ETFBDYN1.44 مليون0.05%3.16 مليار USD0.40%28.1232 US$+0.69%
Adasina Social Justice All Cap Global ETFJSTC1.1 مليون0.37%301.45 مليون USD0.89%22.80 US$+0.95%
iShares Flexible Equity Active ETFBFLX1.04 مليون0.05%2.19 مليار USD0.40%26.1102 US$+0.67%First Trust Value Line Dividend Index FundFVDVanEck Pharmaceutical ETFPPHAvantis International Equity ETFAVDEActivePassive International Equity ETFAPIEVanguard FTSE All-World ex-US ETFVEUiShares Dynamic Equity Active ETFBDYNAdasina Social Justice All Cap Global ETFJSTCiShares Flexible Equity Active ETFBFLXالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
